ofloxacin has been researched along with moxifloxacin in 364 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (2.20) | 18.2507 |
| 2000's | 222 (60.99) | 29.6817 |
| 2010's | 116 (31.87) | 24.3611 |
| 2020's | 18 (4.95) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C | 1 |
| Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Cattoir, V; Mazel, D; Nordmann, P; Poirel, L; Soussy, CJ | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 2 |
| Arsène, S; Leclercq, R | 1 |
| Andres, P; Centrón, D; Galas, M; Guerriero, L; Petroni, A; Quiroga, C; Quiroga, MP; Soler Bistué, AJ; Tokumoto, M; Tolmasky, ME; Vargas, LJ; Zorreguieta, A | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Mayer, C | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Dionisi, AM; Lucarelli, C; Luzzi, I; Owczarek, S; Villa, L | 1 |
| Caddick, JM; Gunell, M; Hakanen, AJ; Huovinen, P; Jalava, J; Kotilainen, P; Lilly, AJ; Piddock, LJ; Siitonen, A; Webber, MA | 1 |
| da Silva, PA; Hoffner, S; Jureen, P; Martin, A; Palomino, JC; Portaels, F; Vandamme, P; Von Groll, A | 1 |
| Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E | 1 |
| Barbut, F; Bouttier, S; Collignon, A; Denève, C; Dupuy, B; Janoir, C | 1 |
| Martínez, JL; Sánchez, MB | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ | 1 |
| Sen, S; Sinha, N | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Anquetin, G; Aubry, A; Capton, E; Gomez, C; Jarlier, V; Lamouri, A; Pantel, A; Ponien, P; Serradji, N | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, L; Fan, L; He, ZQ; Jiang, L; Lei, HS; Liu, CP; Liu, J; Peng, XM; Xu, XR; Yang, DC; Zhou, CH; Zhou, FW; Zou, YY | 1 |
| Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J | 1 |
| Babu, KS; Jeankumar, VU; Reddy, KI; Renuka, J; Shravan, M; Sridevi, JP; Srihari, K; Sriram, D; Yogeeswari, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
| Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Alonso-Rodriguez, N; Briffotaux, J; Buchieri, MV; Cimino, M; Coulibaly, S; Dallemagne, P; Gicquel, B; Lecoutey, C; Mornico, D; Ouattara, M; Rochais, C | 1 |
| Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R | 1 |
| Bauernfeind, A | 1 |
| Hammerschlag, MR; Roblin, PM | 1 |
| Hoban, DJ; Karlowsky, JA; Zhanel, GG | 1 |
| Edlund, C; Nord, CE; Sabouri, S | 1 |
| Ballesta, S; García, I; Pascual, A; Perea, EJ | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 1 |
| Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
| Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C | 1 |
| Bjarnason, J; Blondeau, JM; Laskowski, R; Stewart, C | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Coleman, EJ; Mandell, GL | 1 |
| Firsov, AA; Kononenko, OV; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 1 |
| Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W | 1 |
| Doern, GV; Ernst, EJ; Klepser, ME; Petzold, CR; Rhomberg, P | 1 |
| Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M | 1 |
| Hedges, AJ; MacGowan, AP; Sunderland, J; Tobin, CM; White, LO | 1 |
| Lister, PD | 1 |
| Cheon, SH; Dietze, R; Ellner, JJ; Hise, AG; Landen, K; Palaci, M; Phillips, M; Ribeiro, FC; Song, HY; Vinhas, S; Wallis, RS | 1 |
| Climent, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Black, J; Chartrand, SA; Moland, ES; Thomson, KS | 1 |
| Johnson, AP; Livermore, DM; Warner, M | 1 |
| Lister, PD; Sanders, CC | 1 |
| Everett, D; Gillespie, SH; Morrissey, I | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Appelbaum, PC; Davies, T; Edlund, C; El Amin, N; Oh, H | 1 |
| Adrián, F; del Campo, R; García, C; Gómez-Lus, P; Gómez-Lus, R; Rubio, MC; Sánchez, S | 1 |
| Georgopoulos, A; Graninger, W; Grisold, A; Mueller-Uri, P; Presterl, E | 1 |
| Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V | 1 |
| Rossi, C; Sternon, J | 1 |
| Piddock, LJ; Ricci, V | 1 |
| Arias-Puente, A; Carrasco-Font, C; Fresnadillo-Martinez, MJ; García-Sáenz, MC | 1 |
| Barrett, JF; Chaniewski, S; Frosco, M; Hooper, DC; Lawrence, LE; Ryan, B; Yang, H | 1 |
| Berkovitch, M; Bolkovshtein, M; Lederman, N | 1 |
| Frothingham, R | 2 |
| Drlica, K; Li, X; Zhao, X | 1 |
| Blondeau, JM | 1 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
| Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I | 1 |
| Karenchak, LM; Kowalski, RP; Mather, R; Romanowski, EG | 1 |
| Appelbaum, PC; Bozdogan, B; Clark, CL; Davies, TA; Dewasse, B; Jacobs, MR; Nagai, K | 1 |
| Brinker, A; Staffa, J | 1 |
| Appelbaum, PC; Bozdogan, B; Browne, FA; Clark, C; Dewasse, BE; Jacobs, MR | 1 |
| Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 2 |
| Bercion, R; Carricajo, A; Celard, M; Chomarat, M; Croizé, J; Delubac, F; Fèvre, D; Frédénucci, I; Fuhrmann, C; Helfre, M; Lelièvre, H; Letouzey, MN; Mandjee, A; Marthelet, P; Meley, R; Perrier-Gros-Claude, JD; Ros, A; Roure, C; Smati, S; Thierry, J; Tous, J | 1 |
| Behra-Miellet, J; Dubreuil, L; Jumas-Bilak, E | 1 |
| López, M; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE | 1 |
| Bello, S; Torres, A | 1 |
| Ariano, RE; Harding, GK; Iacovides, H; Sun, S; Zelenitsky, SA | 1 |
| Abels, R; Chien, S; Goodman, DB; Hunt, TL; Natarajan, J; Noel, GJ | 1 |
| Häfner, H; Klik, S; Lemmen, SW; Lütticken, R; Zolldann, D | 1 |
| Horcajada, JP; Martínez, JA | 1 |
| Dalhoff, A; Shalit, I | 1 |
| López, M; Rodriguez Díaz, JC; Royo, G; Ruiz, M | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Ameyama, S; Shinmura, Y; Takahata, M | 1 |
| Aguilar, L; Garcia-Mendez, E; Jiménez De Anta, MT; Marco, F; Mensa, J; Ruiz, J; Sierra, JM; Vila, J | 1 |
| Allen, GP; Kaatz, GW; Rybak, MJ | 1 |
| Bosso, JA; Enzweiler, KA; White, RL | 1 |
| Carter, O; Counts, C; Dodson, S; Lody, C; Madhusudhan, KT; Ojha, N | 1 |
| Piddock, L; Ricci, V | 1 |
| Dhaliwal, DK; Gordon, YJ; Karenchak, LM; Kowalski, RP; Mah, FS; Ritterband, DC; Romanowski, EG | 1 |
| Leggett, J; Saravolatz, LD | 1 |
| Choi, JH; Choi, SM; Kim, SH; Lee, DG; Shin, WS; Song, MJ; Yoo, JH | 1 |
| Garrison, MW; Madaras-Kelly, KJ; Schimmels, JA | 1 |
| Aracil, B; Campos, J; Cantón, R; Pérez-Vázquez, M; Román, F | 1 |
| Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C | 1 |
| Hwang, DG | 1 |
| Elliott, MA; Patel, R; Prabhu, RM | 1 |
| Florea, NR; Nicolau, DP; Nightingale, CH; Tessier, PR; Zhang, C | 1 |
| Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S | 1 |
| Bergoin, E; Charles, PE; Chavanet, P; Croisier, D; Etienne, M; Lequeu, C; Piroth, L; Portier, H | 1 |
| Martinez, FJ | 1 |
| Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA; Traidej, M | 1 |
| Burkhardt, O; Köhnlein, T; Pap, T; Welte, T | 1 |
| Chuah, SK; Gollapudi, S; Thadepalli, H | 1 |
| Bernabo, J; Eiguchi, K; Farinati, A; Miller, RD; Molestina, RE; Ramirez, JA; Summersgill, JT; Uriarte, SM | 1 |
| Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Schooley, S; Stein, GE | 1 |
| Bast, DJ; Bell, D; Chen, X; de Azavedo, JC; Dresser, L; Low, DE; Mandell, LA; Saskin, R; Yue, M | 1 |
| Greisman, J; Hoban, CJ; Hoban, DJ; Noreddin, AM; Schurek, KN; Siemens, CG; Smith, HJ; Zhanel, GG | 1 |
| Ba, BB; Grellet, J; Nguyen, HA; Quentin, C; Saux, MC | 1 |
| Bouros, DE; Kottakis, I; Liapakis, IE; Light, RW; Pitiakoudis, MS; Simopoulos, CE; Tsatsakis, AM; Tzatzarakis, MN; Ypsilantis, P | 1 |
| Alou, L; Cafini, F; Prieto, J; Sevillano, D; Valero, E | 1 |
| Drlica, K; Li, X; Mariano, N; Rahal, JJ; Urban, CM | 1 |
| García-Tapia, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Hoepelman, I | 1 |
| Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D | 1 |
| Hermsen, ED; Hovde, LB; Rodvold, KA; Rotschafer, JC; Sprandel, KA | 1 |
| Barcia-Macay, M; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Hermsen, ED; Hovde, LB; Konstantinides, GN; Rotschafer, JC | 1 |
| Holzgrabe, U; Kiefer, W; Neugebauer, U; Popp, J; Schmitt, M; Szeghalmi, A | 1 |
| Berger, RE | 1 |
| Michot, JM; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| De Vecchi, E; Drago, L; Legnani, D; Nicola, L; Prenna, M; Ripa, S | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Baltch, AL; Bopp, LH; Michelsen, PB; Ritz, WJ; Smith, RP | 1 |
| Anon, JB | 1 |
| Cabeza, JG; Hernandez, J; Llagostera, M; Mensa, J; Montero, T; Ruiz Chaler, M; Sierra, JM; Vila, J | 1 |
| Almela, M; Jurado, A; Marco, F; Mensa, J; Ortega, M; Soriano, A | 1 |
| Abelson, MB; Shapiro, A; Torkildsen, G; Wagner, RS | 1 |
| Jung, HC; Kim, JM; Kim, JS; Kim, N; Song, IS | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Alegakis, D; Falagas, M; Falagas, ME; Gikas, AH; Kofteridis, DP; Mantadakis, E; Maraki, S; Papadakis, JA; Samonis, G | 1 |
| Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS | 1 |
| Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI | 1 |
| Depta, JP; Pichler, WJ; Schmid, DA | 1 |
| Caballero, AR; Dajcs, JJ; Johnston, KH; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Friedman, HS; Keating, KN; Perfetto, EM | 1 |
| Cox, CD; Meyerrose, GE; Peeters, MJ; Seifert, CF; Tsikouris, JP | 1 |
| Alexandrou, AJ; Duncan, RS; Hancox, JC; Leaney, JL; Leishman, DJ; Sullivan, A; Witchel, HJ | 1 |
| Cornish, W; Knowles, S; Phillips, EJ; Rachlis, A; Simor, AE; Tailor, SA | 1 |
| Amábile-Cuevas, CF; Ariza, H; Caballero, A; García-Calderón, A; Hernández-Oliva, G; Jardim, JR; Urueta-Robledo, J; Vivar-Orozco, R | 1 |
| Dalhoff, A; Schubert, S; Stass, H; Ullmann, U | 1 |
| Alou, L; del Carmen Ponte, M; Gracia, M; Huelves, L; López-Casla, MT; Martínez-Marín, C; Prieto, J; Sevillano, D; Soriano, F | 1 |
| Siewert, S | 1 |
| Kamel, AG; Lim, VK; Norazah, A; Rohani, MY | 1 |
| Chan, MY; Cheung, TL; Kam, KM; Leung, OC; Tang, HS; Yip, CW | 1 |
| Lück, PC; Steinert, M | 1 |
| Ackermann, T; Bertram, N; Paar, WD; Sauerbruch, T; Schulte, S | 1 |
| Chan, KP; Choy, KW; Chu, KO; Lai, WW; Lam, DS; Pang, CP; Wang, CC | 1 |
| Alefelder, M; Arvis, P; Cronjé, HS; Kureishi, A; Paszkowski, T; Rakoczi, I; Reimnitz, P; Ross, JD; Vildaite, D | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Black, JA; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Bayar, B; Bozkurt, A; Dinçel, A; Duman, S; Kaya, E; Oflu, Y; Yağci, R; Yağci, S | 1 |
| De Benedetto, L; De Benedetto, M; Passali, D; Passali, GC; Salerni, L | 1 |
| Aydemir, S; Cilli, F; Tunger, A | 1 |
| Boom, WH; Charlebois, ED; Daley, CL; Debanne, SM; Dietze, R; Eisenach, KD; Hadad, DJ; Jankus, DD; Johnson, JL; Maciel, E; Palaci, M; Peloquin, CA | 1 |
| Aguilar, L; Alou, L; Cafini, F; Echeverría, O; Giménez, MJ; Pérez-Trallero, E; Prieto, J; Sevillano, D | 1 |
| Deryke, CA; Du, X; Nicolau, DP | 1 |
| Bommer, M; Döhner, H; Kern, P; Kern, WV; Marre, R; Reuter, S; Sigge, A; von Baum, H | 1 |
| Krause, R; Laferl, H; Széll, M; Wenisch, C | 1 |
| Cars, O; Odenholt, I | 1 |
| Dhalla, IA; Juurlink, DN; Kopp, A; Mamdani, MM; Rochon, PA; Simor, AE | 1 |
| Hand, DL; Hand, WL; Vasquez, Y | 1 |
| Asbell, PA; Bottone, EJ; Epstein, SP | 1 |
| Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, C | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG | 1 |
| Fiscella, RG; Jensen, MK | 1 |
| Aloisi, GG; Amelia, M; Barbafina, A; Canton, M; Dall'Acqua, F; Elisei, F; Facciolo, L; Latterini, L; Vedaldi, D; Viola, G | 1 |
| Rodríguez, JC; Royo, G; Ruiz, M; Sirvent, E | 1 |
| DeRyke, CA; Doern, GV; Du, X; Nicolau, DP; Sun, HK | 1 |
| D'Azevedo, PA; Francisco, W; Oliveira, AD | 1 |
| Biller, P; Brennan, M; Killgore, G; Lind, L; McDonald, LC; Shank, B; Thompson, A; Tkatch, L | 1 |
| Amyes, SG; Dobay, O; Ghidán, A; Matuz, M; Nagy, K; Rozgonyi, F | 1 |
| Catero, M | 1 |
| Kaatz, GW; LaPlante, KL; Lodise, TP; Rybak, MJ; Tsuji, B | 1 |
| Gidoh, M | 1 |
| DeRyke, AC; Fan, HW; Lee, SY; Nicolau, DP; Sutherland, C | 1 |
| Bower, KS; Colyer, MH; Dick, JS; Haller, JA; Ward, TP; Weber, ED; Weichel, ED | 1 |
| Haggerty, CL; Ness, RB | 1 |
| Dubois, V; Grellet, J; Nguyen, HA; Quentin, C; Saux, MC | 1 |
| Breithardt, G; Cakir, Y; Eckardt, L; Engelen, MA; Haverkamp, W; Hilker, E; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Stypmann, J | 1 |
| Blondeau, JM; Borsos, S; Hesje, CK | 1 |
| Hart, D; Weinstein, MP | 1 |
| Blondeau, JM; Hedlin, P | 1 |
| Choi, EC; Choi, JS; Joo, CK; Kim, SY; Lim, JA | 1 |
| Chan, KP; Choy, KW; Chu, KO; Lai, WW; Pang, CP; Tsang, CW; Wang, CC | 1 |
| Homma, T; Hori, T; Sugimori, G; Yamano, Y | 1 |
| Czock, D; de Groot, K; Fliser, D; Hafer, C; Haller, H; Hüsig-Linde, C; Keller, F; Kielstein, JT; Kuse, E; Langhoff, A; Schöpke, T; Swoboda, S | 1 |
| Fukushima, K; Higashiyama, Y; Hirakata, Y; Kohno, S; Kohno, Y; Miyazaki, Y; Ohno, H; Yanagihara, K | 1 |
| Constantinou, M; Daniell, M; Snibson, GR; Taylor, HR; Vu, HT | 1 |
| Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K | 1 |
| Hovde, LB; Rotschafer, JC; Schafer, J; Simonson, D | 1 |
| Citron, DM; Goldstein, EJ; Nicolau, DP; Schooley, S; Stein, GE; Tyrrell, KL | 1 |
| Hovde, LB; Rotschafer, JC; Simonson, DA | 1 |
| Boom, WH; Dietze, R; Hadad, DJ; Johnson, JL; Molino, LP; Palaci, M; Peloquin, CA | 1 |
| Bezwada, P; Clark, LA; Schneider, S | 1 |
| Chang, ST; Chen, CC; Cheng, KC; Chuang, YC; Huang, HC; Shieh, CC; Yu, WL | 1 |
| Inoue, T; Kida, T; Naka, H; Sakaki, H; Tokushige, H; Wada, T | 1 |
| Allen, J; Coleman, DJ; Davies, GR; Fourie, B; Kanyok, T; Levin, J; Lienhardt, C; Mitchison, DA; Mthiyane, T; Reddy, C; Rustomjee, R; Sirgel, FA; Sturm, AW | 1 |
| Alexiadou, E; Grovaris, L; Lazaraki, G; Metallidis, S; Nikolaidis, J; Nikolaidis, P; Theodoridou, A; Topsis, D | 1 |
| Hatou, S; Yamada, M; Yoshida, J | 1 |
| Galles, AC; Jones, RN; Sader, HS | 1 |
| Evers, T; Holman, A; Lloyd, A | 1 |
| Carroll, DG; Carroll, DN | 1 |
| Arvis, P; Carlet, J; Choudhri, S; Garau, J; Kureishi, A; Le Berre, MA; Lode, H; Read, RC; Torres, A; Winter, J | 1 |
| Doshi, D; Grant, R; Janagap-Benson, C; Olson, W; Schein, J; Sikirica, V | 1 |
| Hatou, S; Minagawa, Y; Yamada, M; Yoshida, J; Yoshida, T | 1 |
| Eisen, L; Kim, J; Rosenberg, J | 1 |
| Dubois, V; Grellet, J; Nguyen, HA; Quentin, C; Saux, MC; Tulkens, PM; Van Bambeke, F; Van de Velde, S | 1 |
| Mullangi, R; Narasu, L; Shankar, BP; Srinivas, N | 1 |
| Kim, SY; Lee, YC; Park, YH | 1 |
| Baines, SD; Freeman, J; O'Connor, R; Saxton, K; Wilcox, MH | 1 |
| Fiscella, RG; Jensen, MK; Mooney, B; Moshirfar, M | 1 |
| Asbell, PA; Epstein, SP; Sosa, AB | 1 |
| Scoper, SV | 1 |
| Qi, HM; Wei, MJ; Zhang, L; Zhao, CY | 1 |
| Aihara, M; Eguchi, S; Minami, K; Miyanaga, M; Miyata, K; Sawaguchi, S; Shiroma, H | 1 |
| Baietto, L; D'Avolio, A; De Rosa, FG; Di Perri, G; Garazzino, S; Patanella, S; Sciandra, M; Siccardi, M | 1 |
| Choi, JS; Joo, CK; Kim, KA; Lim, JA; Park, SH | 1 |
| Meletiadis, J; Papaioannidou, P; Roilides, E; Sein, T; Stergiopoulou, T; Tsiouris, I; Walsh, TJ | 1 |
| Holland, EJ; Lane, SS; Lindstrom, RL | 1 |
| McCulley, JP | 1 |
| Ariza, J; Cabellos, C; Cabo, J; Euba, G; Gudiol, F; Murillo, O; Pachón, ME; Tubau, F; Verdaguer, R | 1 |
| Alam, MR; Garg, P; Gopinathan, U; Krishnaiah, S; Reddy, AK; Sharma, S | 1 |
| García-Rodríguez, JA; Lázaro, FG; Muñoz-Bellido, JL; Rodríguez-Tarazona, RE | 1 |
| Hori, Y; Inoue, T; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Sakamoto, M; Tano, Y; Yokokura, S | 1 |
| Boussery, K; Colpaert, K; De Paepe, P; De Smet, J; De Sutter, P; Decruyenaere, J; Van Bocxlaer, J | 1 |
| Barbanti, F; Barbut, F; Louie, T; Mastrantonio, P; Spigaglia, P | 1 |
| Chen, YC; Ho, CC; Hu, FC; Luh, KT; Yang, PC; Yu, CJ | 1 |
| Allen, GP; Hankins, CD | 1 |
| Carmona, IT; Diz Dios, P; Limeres Posse, J; Núñez Otero, V | 1 |
| Chen, WL; Hu, FR; Tsai, TH | 1 |
| Blondeau, JM; Borsos, SD; Hesje, CK | 1 |
| Carda-Broch, S; Esteve-Romero, J; Rambla-Alegre, M | 1 |
| Fisher, AC; Grant, R; Gu, A; Mody, SH; Ng, D; Raut, M; Schein, J; Sengupta, A; Sheng Duh, M; Signorovitch, JE | 1 |
| Appelbaum, PC; Credito, K; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Anisimov, BI; Ryzhko, IV; Trishina, AV; Tsuraeva, RI | 1 |
| Bell, B; D'Arienzo, PA; Dajcs, JJ; Jamison, T; Stroman, DW; Wagner, RS | 1 |
| Boothby, M; Page, J; Pryor, R; Ross, JD | 1 |
| Berdeaux, G; Khoshnood, B; Kodjikian, L; Lafuma, A; Laurendeau, C | 1 |
| Chang, CM; Chen, PC; Chen, PL; Ko, WC; Lauderdale, TL; Lee, CC; Lee, HC; Lee, NY; Wu, CJ | 1 |
| Disratthakit, A; Doi, N | 1 |
| Arezina, R; Camm, AJ; Harada, T; Lorch, U; Naseem, A; Taubel, J; Wang, D | 1 |
| Beksac, MS; Katlan, D; Kir, S; Nemutlu, E; Ozyuncu, O | 2 |
| Chan, RC; Chang, KC; Yew, WW | 1 |
| Huang, X; Li, Y; Shi, R; Yao, L; Zhang, G | 1 |
| Hsueh, PR; Lee, PI; Yang, JC | 1 |
| Arvis, P; Hampel, B; Judlin, P; Liao, Q; Liu, Z; Reimnitz, P | 1 |
| Andreu, I; Aranda, A; Ariza, A; Blanca-Lopez, N; Doña, I; Mayorga, C; Rosado, A; Torres, MJ | 1 |
| Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N | 1 |
| Schafer, KR; Wispelwey, B | 1 |
| Barbounakis, E; Kofteridis, DP; Lionakis, S; Maraki, S; Ntaoukakis, M; Ntasis, E; Samonis, G | 1 |
| Aracil, B; Campos, J; Cuevas, O; de Abajo, F; García-Cobos, S; Lázaro, E; Ortega, A; Oteo, J | 1 |
| Baba, S; Fujisawa, T; Harabuchi, Y; Ikeda, F; Kobayashi, T; Kurono, Y; Nishimura, T; Suzuki, K; Ubukata, K; Yamanaka, N | 1 |
| Bhagunde, P; Chang, KT; Ledesma, KR; Nikolaou, M; Singh, R; Tam, VH | 1 |
| Kim, SJ; Toma, HS | 1 |
| Ghasemzadeh, A; Mobarez, AM; Taghvaei, T; Talebi Bezmin Abadi, A | 1 |
| Decramer, M; Peetermans, WE; Simoens, S; van Bleyenbergh, P; Verhaegen, J | 1 |
| Gerding, DN; Johnson, S; Nagaro, K; Phillips, ST; Sambol, SP | 1 |
| Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS | 1 |
| Biedenbach, DJ; Farrell, DJ; Jones, RN; Liverman, LC | 1 |
| Dan, M; Rosenberg, S; Samra, Z | 1 |
| Chamseddin, C; Jira, TH | 1 |
| Green, K; Low, DE; McGeer, A; Melano, R; Patel, SN; Pillai, DR; Tyrrell, GJ | 1 |
| Dunbar, D; El Sahly, HM; Graviss, EA; Jost, KC; Lew, J; Teeter, LD | 1 |
| Chung, HS; Han, SK; Kim, DK; Kim, JY; Kim, YW; Lee, CH; Lee, CT; Lee, J; Lee, JH; Lee, SM; Yang, SC; Yim, JJ; Yoo, CG; Yoon, HI | 1 |
| Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M | 1 |
| Berning, M; Krasz, S; Labenz, J; Miehlke, S; Morgner, A | 1 |
| Dave, SB; Kim, SJ; Toma, HS | 2 |
| Alekperov, SI; Boĭko, ÉV; Fokina, DV; Reĭtuzov, VA | 1 |
| Menchini, U; Mencucci, R; Paladini, I; Pellegrini-Giampietro, DE; Scartabelli, T | 1 |
| Furukawa, T; Goto, H; Ito, N; Miyake, T; Tajima, K | 1 |
| Biedenbach, DJ; Farrell, DJ; Flamm, RK; Jones, RN; Liverman, LC; McIntyre, G | 1 |
| Chen, X; Guo, X; Shi, G; Wang, H; Wang, S; Zhang, X | 1 |
| Böttger, EC; Sirgel, FA; Streicher, EM; van Helden, PD; Victor, TC; Warren, RM | 1 |
| Garg, S; Milder, E; Shah, C; Vander, J | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Hsueh, PR; Ko, WC; Liao, CH; Lu, JJ | 1 |
| Fukuda, M; Hori, Y; Inatomi, T; Kinoshita, S; Kubota, A; Maeda, N; Nakazawa, T; Nishida, K; Ohashi, Y; Satake, Y; Shimazaki, J; Shimomura, Y; Uno, T; Yamada, M | 1 |
| Chavda, K; Drlica, K; Hussain, S; Kerns, RJ; Kreiswirth, BN; Kurepina, N; Malik, M; Shah, N; Zhao, X | 1 |
| Malithong, A; Phiboonbanakit, D; Santiwatanakul, S; Srisangchan, P; Srisurat, N; Susaengrat, W; Tantisiriwat, W; Thamlikitkul, V; Thunyaharn, S; Tiengrim, S | 1 |
| Absi, M; Ghareeb, H; Khalil, A; Ruegg, UT | 1 |
| Ayaki, M; Iwasawa, A; Niwano, Y | 1 |
| Bourdon, O; Chauny, JV; De Lauzanne, A; Doit, C; Géréral, T; Lorrot, M; Prot-Labarthe, S | 1 |
| Castanheira, M; Farrell, DJ; Jones, RN; Turner, LL | 1 |
| Albini, A; Fasani, E; Maraschi, F; Migliavacca, R; Nucleo, E; Pretali, L; Profumo, A; Speltini, A; Sturini, M | 1 |
| Fortier, LC; Meessen-Pinard, M; Sekulovic, O | 1 |
| Bukatina, AA; Galkina, KY; Isaeva, YD; Makarova, MV; Moroz, AM; Nosova, EY | 1 |
| Kawasaki, S; Mito, T; Ohashi, Y; Suzuki, T; Tasaka, Y; Uda, T; Uno, T | 1 |
| Bowker, KE; Garvey, MI; Macgowan, AP; Noel, AR; Tomaselli, SG | 1 |
| Ahmad, Z; Grosset, JH; Minkowski, A; Nuermberger, EL; Peloquin, CA; Tyagi, S | 1 |
| Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV | 1 |
| Chang, KC; Dheda, K | 1 |
| Diethelm, M; Schuster, S | 1 |
| Aubry, A; Brossier, F; Chauffour, A; Fillion, A; Jarlier, V; Veziris, N | 1 |
| Ark, C; Aşicioğlu, O; Ertas, IE; Gungorduk, K; Ozdemir, A; Sanci, M; Yildirim, G | 1 |
| Duan, J; Hayes, D; Li, X; Mansour, HM; Vogt, FG | 1 |
| Lu, J; Pang, Y; Wang, Y; Zhang, Z; Zhao, Y | 1 |
| Charalambous, S; Chigutsa, E; Denti, P; Harrison, T; Hatherill, M; Jindani, A; McIlleron, HM; Mungofa, S; Simonsson, US; Sirgel, FA; Wiesner, L; Zvada, SP | 1 |
| Cachovan, G; Eick, S; Nietzsche, S; Sculean, A; Tsaousoglou, P | 1 |
| Gratz, J; Heysell, SK; Houpt, ER; Kibiki, GS; Kumburu, H; Mpagama, SG; Ndusilo, N; Peloquin, CA; Stroup, S | 1 |
| Jo, KW; Kim, DS; Kim, WS; Lee, SD; Shim, TS | 1 |
| Ajbani, K; Catanzaro, A; Caviedes, L; Coronel, J; Crudu, V; Desmond, E; Eisenach, K; Ganiats, TG; Garfein, RS; Groessl, EJ; Jackson, RL; Klages, S; Moore, D; Rodrigues, C; Rodwell, TC; Romancenco, E; Trollip, AP; Victor, T; Vineet, VP | 1 |
| Amorim, CL; Barreiro, JC; Cass, QB; Castro, PM; Maia, AS; Ribeiro, AR; Tiritan, ME | 1 |
| Ang, TL; Song, M | 1 |
| Djurdjevic, P; Ivanovic, N; Jakovljevic, I; Jelikic-Stankov, M; Joksovic, L | 1 |
| Ajbani, K; Catanzaro, A; Kambli, P; Nikam, C; Rodrigues, C; Rodwell, TC; Sadani, M; Shetty, A; Udwadia, Z | 1 |
| Babu, S; Chhajed, P; Dalal, A; Das, M; Desai, R; Isaakidis, P; Jayalakshmi, TK; Pawaskar, A; Prabhudesai, P; Rajan, S; Reddy, D; Rodrigues, C; Saranchuk, P | 1 |
| Bisht, D; Deo, N; Kumar, B; Lata, M; Sharma, D; Tiwari, PK; Venkatesan, K | 1 |
| Farhat, MR; Franke, MF; Jacobson, KR; Kaur, D; Mitnick, CD; Murray, M; Sloutsky, A | 1 |
| Donald, PR; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Thee, S | 1 |
| Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC | 1 |
| Cass, QB; Denadai, M | 1 |
| Chiang, CJ; Chien, JY; Chien, ST; Chiu, WY; Hsueh, PR; Yu, CJ | 1 |
| Hassan, M; Iqbal, Z; Khan, FU; Khan, I; Nasir, F; Shahbaz, N; Ullah, F | 1 |
| Chien, JY; Chien, ST; Chiu, WY; Hsueh, PR; Yu, CJ | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Chen, S; Dong, L; Huang, H; Köser, CU; Moradigaravand, D; Parkhill, J; Peacock, SJ; Schön, T; Shang, Y; Wang, G; Wei, G; Yu, X | 1 |
| Aubry, A; Bernard, C; Brossier, F; Chauffour, A; Robert, J; Veziris, N | 1 |
| Head, BM; Meyers, AF; Rubinstein, E | 1 |
| Bao, L; Luo, T; Mi, Y; Peng, X; Sun, C; Wang, C; Yang, G; Yuan, J; Zhang, C | 1 |
| Campanerut-Sá, PAZ; Cardoso, RF; Ghiraldi-Lopes, LD; Meneguello, JE; Pavan, FR; Scodro, RBL; Siqueira, VLD; Svidzinski, TIE; Teixeira, JJV | 1 |
| Bonato, PS; Faria-E-Sousa, SJ; Jabor, VAP; Martinez, EZ; Silva, GCM | 1 |
| Chen, YH; Huang, CH; Kuo, CY; Lu, PL; Wang, WH | 1 |
| Mamatha, HG; Shanthi, V | 1 |
| Clifton, DA; Crook, DW; Iqbal, Z; Niehaus, KE; Peto, TEA; Smith, EG; Walker, AS; Walker, TM; Wilson, DJ; Yang, Y; Zhu, T | 1 |
| Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM | 1 |
| Kurz, X; McGettigan, P; Morales, D; Pacurariu, A; Pinheiro, L; Slattery, J | 1 |
| Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA | 1 |
| Capparelli, E; Catanzaro, DG; Rodwell, TC; Seifert, M | 1 |
| He, YC; Huang, JH; Li, LJ; Li, YF; Liang, LY; Wang, K; Xu, FY; Yang, J; Zheng, QS | 1 |
| Alffenaar, JW; Bruchfeld, J; Davies Forsman, L; Eliasson, E; Hoffner, S; Hong, C; Hu, Y; Ke, R; Kuhlin, J; Niward, K; Paues, J; Schön, T; Simonsson, USH; Werngren, J; Xu, B; Zheng, R; Zheng, X | 1 |
| Draper, HR; Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; van der Laan, LE; Winckler, JL | 1 |
| Bucsa, C; Farcas, A; Huruba, M; Leucuta, DC; Mogosan, C; Sipos, M | 1 |
| Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T | 1 |
| Guo, Y; Liu, H; Sha, W; Shen, H; Shen, X; Tan, G; Wu, X; Wu, Z; Yang, J; Yu, F | 1 |
| Hand, RA; Henderson, A; Sullivan, MV; Turner, NW | 1 |
| Guo, Y; Huang, C; Sha, W; Tan, G; Wu, X; Yang, J; Yu, F | 1 |
| Bland, MJ; Gabant, P; Gala, JL; Martin, A; Rodriguez-Villalobos, H | 1 |
| Gao, Y; Ji, Y; Lin, Y; Lin, Z; Lu, Y; Yang, Y; Zhang, L | 1 |
| Alavi, A; Bayatloo, MR; Nojavan, S; Salehpour, N | 1 |
| Agrawal, D; Chatterjee, S; Gangwe, AB; Gomase, SN; Mishra, M; Parchand, SM | 1 |
| Abou-Seri, SM; Elanany, MA; Gedawy, EM; Osman, EEA | 1 |
| Fu, D; Geng, J; Jiang, J; Li, B; Lu, L; Ma, L; Meng, F; Qi, H; Shen, J; Sun, S; Yabo, SD | 1 |
| Adams, KK; Clarke, LG; Shah, S | 1 |
| Eid, M; El-Sayed, A; Elmansi, HM; Shalan, S | 1 |
26 review(s) available for ofloxacin and moxifloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
Quinolone antibiotics.
Topics: | 2019 |
[Third and fourth generation fluoroquinolones].
Topics: Administration, Oral; Anti-Infective Agents; Aza Compounds; Belgium; Biological Availability; Drug Monitoring; Drug Resistance; Fluoroquinolones; Gemifloxacin; Humans; Intestinal Absorption; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Patient Selection; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Time Factors; Treatment Outcome | 2001 |
[The safety of new quinolone treatment--levoflaxacin (tavanic) and moxiflocacin (megaxin)-- in the community].
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Moxifloxacin; Ofloxacin; Quinolines; Safety | 2001 |
The role of fluoroquinolones in skin and skin structure infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clinical Trials as Topic; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Skin Diseases, Bacterial; Staphylococcus aureus; Streptococcus | 2002 |
Immunomodulatory effects of quinolones.
Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clinical Trials as Topic; Cytokines; Fluoroquinolones; Humans; Immune System; Models, Animal; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2003 |
Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2004 |
[New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Pneumonia; Quinolines; Respiratory Tract Infections | 2004 |
Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; Clinical Trials as Topic; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Meta-Analysis as Topic; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Quinolines; Rhinitis; Sinusitis; Streptococcus pneumoniae | 2005 |
[Pathogenesis, diagnosis and therapy of Legionella infections].
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Aza Compounds; Azithromycin; Ciprofloxacin; Diagnosis, Differential; DNA, Bacterial; Fluoroquinolones; Humans; Incidence; Legionella; Legionella pneumophila; Legionellosis; Legionnaires' Disease; Levofloxacin; Moxifloxacin; Ofloxacin; Polymerase Chain Reaction; Quinolines; Serotyping; Virulence | 2006 |
[Rhinosinusitis: etiopathogenesis and antimicrobial therapy, an update].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria; Child; Drug Resistance, Microbial; Endoscopy; Fluoroquinolones; Humans; Moxifloxacin; Mucociliary Clearance; Nasal Decongestants; Ofloxacin; Prevalence; Quinolines; Recurrence; Retrospective Studies; Risk; Sinusitis; Time Factors; Tomography, X-Ray Computed | 2006 |
Dysglycemia and fluoroquinolones: are you putting patients at risk?
Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Evidence-Based Medicine; Family Practice; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Incidence; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; United States; United States Food and Drug Administration | 2007 |
Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Microbial; Female; Fluoroquinolones; Follow-Up Studies; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pelvic Inflammatory Disease; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2007 |
Interactions between warfarin and three commonly prescribed fluoroquinolones.
Topics: Aza Compounds; Ciprofloxacin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluoroquinolones; Humans; International Normalized Ratio; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Warfarin | 2008 |
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
Topics: Administration, Topical; Anti-Bacterial Agents; Aza Compounds; Endophthalmitis; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2008 |
Efficacy of fluoroquinolones against pathogenic oral bacteria.
Topics: Aza Compounds; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Mouth Diseases; Moxifloxacin; Ofloxacin; Oral Medicine; Quinolines | 2009 |
[Efficacy of moxifloxacin in treating bacterial conjunctivitis: a meta-analysis].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Conjunctivitis, Bacterial; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Odds Ratio; Ofloxacin; Ophthalmic Solutions; Patient Dropouts; Placebos; Quinolines; Randomized Controlled Trials as Topic; Remission Induction; Risk Factors; Treatment Failure; Treatment Outcome | 2010 |
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Aza Compounds; Bacterial Proteins; DNA Gyrase; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Sensitivity and Specificity; Tuberculosis, Multidrug-Resistant | 2010 |
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Proton Pump Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Retreatment | 2010 |
Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumonia, Bacterial; Primary Health Care; Quinolines; Streptococcus pneumoniae | 2010 |
[Current value of quinolones in Helicobacter pylori therapy].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2011 |
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors | 2014 |
Fluoroquinolones for the treatment of tuberculosis in children.
Topics: Age Factors; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Alternative pre-approved and novel therapies for the treatment of anthrax.
Topics: Alpha-Globulins; Anthrax; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Bacterial; Antitoxins; Bacillus anthracis; Bacterial Toxins; Daunorubicin; DNA Helicases; Doxorubicin; Drug Discovery; Fluoroquinolones; Humans; Interferon Inducers; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Polyketides; Serine Proteinase Inhibitors; Tilorone; Virulence | 2016 |
Systematic review on the proteomic profile of Mycobacterium tuberculosis exposed to drugs.
Topics: Anti-Bacterial Agents; Electrophoresis, Gel, Two-Dimensional; Fluoroquinolones; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Proteome; Proteomics; Streptomycin | 2017 |
28 trial(s) available for ofloxacin and moxifloxacin
| Article | Year |
|---|---|
Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Ciprofloxacin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Tissue Distribution | 2001 |
Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Azithromycin; Bronchoalveolar Lavage Fluid; Extravascular Lung Water; Female; Fluoroquinolones; Humans; Levofloxacin; Lung; Macrophages, Alveolar; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Urea | 2004 |
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines | 2005 |
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Safety | 2006 |
Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Topics: Analysis of Variance; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Long QT Syndrome; Male; Moxifloxacin; Ofloxacin; Quinolines; Statistics, Nonparametric; Torsades de Pointes | 2006 |
Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latin American Cohort.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Argentina; Aza Compounds; Brazil; Bronchitis, Chronic; Colombia; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Mexico; Middle Aged; Moxifloxacin; Ofloxacin; Peru; Prospective Studies; Quinolines; Treatment Outcome | 2006 |
Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metronidazole; Moxifloxacin; Ofloxacin; Pain; Pain Measurement; Pelvic Inflammatory Disease; Prospective Studies; Quinolines | 2006 |
Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Single-Blind Method; Tuberculosis, Pulmonary | 2006 |
Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Doxycycline; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Treatment Failure | 2006 |
Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Penicillin Resistance; Quinolines; Serum Bactericidal Test; Streptococcus pneumoniae | 2007 |
Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.
Topics: Adult; Aged; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Chromatography, High Pressure Liquid; Double-Blind Method; Female; Fluoroquinolones; Follow-Up Studies; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Retinal Diseases; Vitrectomy; Vitreous Body | 2007 |
Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacteria; Cefazolin; Child; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Tobramycin; Treatment Outcome | 2007 |
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Brazil; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis, Pulmonary | 2008 |
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Nonlinear Dynamics; Ofloxacin; Pyrazinamide; Quinolines; Rifampin; Sputum | 2008 |
A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Topics: Administration, Oral; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Cost of Illness; Cost-Benefit Analysis; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Length of Stay; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
A comparison of fluoroquinolone penetration into human conjunctival tissue.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Young Adult | 2010 |
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Metronidazole; Middle Aged; Moxifloxacin; Ofloxacin; Pelvic Inflammatory Disease; Quinolines; Treatment Outcome; Young Adult | 2010 |
In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Aza Compounds; Basophil Degranulation Test; Ciprofloxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Immediate; Immunologic Tests; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Radioimmunoassay; Sensitivity and Specificity; Young Adult | 2011 |
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Azithromycin; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Levofloxacin; Middle Aged; Moxifloxacin; Nasopharynx; Ofloxacin; Prospective Studies; Quinolines; Staphylococcal Infections | 2011 |
Ophthalmic antibiotic use and multidrug-resistant staphylococcus epidermidis: a controlled, longitudinal study.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Choroidal Neovascularization; Conjunctiva; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Humans; Intravitreal Injections; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Staphylococcus epidermidis; Young Adult | 2011 |
Comparison of corneal and aqueous humor penetration of moxifloxacin, gatifloxacin and levofloxacin during keratoplasty.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cornea; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2012 |
Changes in ocular flora in eyes exposed to ophthalmic antibiotics.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria; Choroidal Neovascularization; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Longitudinal Studies; Moxifloxacin; Ofloxacin; Quinolines | 2013 |
Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial.
Topics: Adolescent; Adult; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metronidazole; Moxifloxacin; Ofloxacin; Patient Compliance; Pelvic Inflammatory Disease; Quinolines | 2013 |
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
Topics: Adult; Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Moxifloxacin; Ofloxacin; Tuberculosis, Multidrug-Resistant; Young Adult | 2014 |
Relationship between antofloxacin concentration and QT prolongation and estimation of the possible false-positive rate.
Topics: Adult; Anti-Bacterial Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; False Positive Reactions; Female; Healthy Volunteers; Heart Rate; Humans; Long QT Syndrome; Male; Models, Statistical; Moxifloxacin; Ofloxacin; Young Adult | 2020 |
310 other study(ies) available for ofloxacin and moxifloxacin
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Predictive Value of Tests; Quinolines; Time Factors; Tuberculosis | 2007 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Computer Simulation; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleic Acid Amplification Techniques; Open Reading Frames; Plasmids; Polymerase Chain Reaction; Quinolones; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Vibrio | 2007 |
Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacter cloacae; Escherichia coli; France; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Plasmids; Quinolones; Transformation, Genetic | 2007 |
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Culture Media; DNA Gyrase; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Gene Expression Regulation, Bacterial; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid | 2007 |
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones?
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium leprae | 2008 |
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
Topics: Amino Acid Sequence; Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Molecular Sequence Data; Mutagenesis, Site-Directed; Mycobacterium tuberculosis; Protein Structure, Secondary; Quinolones; Sequence Homology, Amino Acid; Structure-Activity Relationship | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium.
Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Evolution, Molecular; Microbial Sensitivity Tests; Multigene Family; Plasmids; Quinolones; Salmonella typhimurium | 2009 |
Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
Topics: Bacterial Proteins; Drug Resistance, Bacterial; Electroporation; Genotype; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Quinolones; Salmonella enterica | 2009 |
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2009 |
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes | 2010 |
Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains.
Topics: Ampicillin; Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Clindamycin; Clostridioides difficile; Cysteine Endopeptidases; DNA Gyrase; Fluoroquinolones; Frameshift Mutation; Immunoblotting; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Polymerase Chain Reaction; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion | 2009 |
SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Mutation; Plasmids; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Stenotrophomonas maltophilia | 2010 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; DNA Cleavage; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium leprae; Mycobacterium tuberculosis; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2013 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
Topics: Antitubercular Agents; Artemisinins; Drug Design; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2014 |
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Topics: Acute Disease; Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Biological Availability; Chronic Disease; DNA Gyrase; Drug Resistance, Bacterial; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Macrophages; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Mutation; Mycobacterium tuberculosis; Piperidines; Protein Subunits; Rats; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tuberculosis, Pulmonary | 2014 |
Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzofurans; Cell Line; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2014 |
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells | 2019 |
Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
Topics: Antitubercular Agents; Drug Design; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Phenanthrolines; Quinolones | 2020 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship | 2022 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Chlamydia Infections; Chlamydophila pneumoniae; Doxycycline; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 1998 |
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin | 1998 |
Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Anaerobic; Cefoxitin; Cephamycins; Clindamycin; Fluoroquinolones; Imipenem; Metronidazole; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Thienamycins | 1998 |
Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cells, Cultured; Ciprofloxacin; Epithelial Cells; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Neutrophils; Ofloxacin; Quinolines; Staphylococcus aureus | 1999 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 1999 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
Activities of antimicrobial agents against intracellular pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Fluoroquinolones; Gentamicins; Humans; Ketolides; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Penicillin G; Quinolines; Rifampin; Streptococcus pneumoniae; Tumor Cells, Cultured | 2000 |
Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Escherichia coli; Fluoroquinolones; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2000 |
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Klebsiella; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Urinary Tract Infections | 2000 |
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Female; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Rabbits; Streptococcus pneumoniae | 2001 |
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.
Topics: Anti-Infective Agents; Aza Compounds; Biological Assay; Chromatography, High Pressure Liquid; Ciprofloxacin; Dose-Response Relationship, Drug; Enterobacter cloacae; Escherichia coli; Fluoroquinolones; Klebsiella; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Photochemistry; Quinolines | 2001 |
Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae | 2001 |
A whole blood bactericidal assay for tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Blood; Blood Bactericidal Activity; Culture Media; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Quinolines; Rifampin | 2001 |
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain | 2001 |
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Child, Preschool; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Lactams; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2001 |
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae | 2001 |
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Ofloxacin; Quinolines | 2001 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Topics: Amino Acid Substitution; Anti-Infective Agents; Aza Compounds; Bacteroides fragilis; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2001 |
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Legionella; Legionellosis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifampin | 2001 |
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Oxazolidinones; Polymerase Chain Reaction; Quinolines; Sensitivity and Specificity; Staphylococcus aureus; Teicoplanin; Vancomycin | 2001 |
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2001 |
Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Norfloxacin; Ofloxacin; Quinolines | 2001 |
Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Topics: Anti-Infective Agents; Aza Compounds; DNA Topoisomerases, Type I; Fluoroquinolones; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Staphylococcus aureus | 2002 |
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Torsades de Pointes | 2001 |
Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Drug Resistance; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Penicillins; Quinolines; Streptococcal Infections; Streptococcus | 2001 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2002 |
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Streptococcus pneumoniae | 2002 |
Concurrent use of selected agents with moxifloxacin: an examination of labeling compliance within 1 year of marketing.
Topics: Anti-Infective Agents; Aza Compounds; Clinical Trials as Topic; Drug Labeling; Fluoroquinolones; Guideline Adherence; Humans; Moxifloxacin; Ofloxacin; Product Surveillance, Postmarketing; Quinolines; United States; United States Food and Drug Administration | 2002 |
Single and multi-step resistance selection study in Streptococcus pneumoniae comparing ceftriaxone with levofloxacin, gatifloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ceftriaxone; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Selection, Genetic; Streptococcus pneumoniae | 2002 |
AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Endpoint Determination; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2002 |
Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Ketolides; Lactams; Levofloxacin; Linezolid; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Penicillin G; Pristinamycin; Quinolines; Streptococcus pneumoniae; Virginiamycin | 2002 |
Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
Topics: Anaerobiosis; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; beta-Lactams; Ciprofloxacin; Clindamycin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2002 |
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.
Topics: Acetamides; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Tuberculosis | 2002 |
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Multivariate Analysis; Mutation; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Pneumonia, Pneumococcal; Quinolines; Recurrence; Risk Factors; Streptococcus pneumoniae | 2003 |
AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Culture Media; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Predictive Value of Tests; Quinolines; Streptococcus pneumoniae | 2003 |
Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Time Factors | 2002 |
Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Aza Compounds; Colony-Forming Units Assay; Escherichia coli; Fluoroquinolones; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Serum Bactericidal Test; Species Specificity; Staphylococcus aureus; Staphylococcus epidermidis | 2003 |
[New antibiotics in primary care].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Family Practice; Fluoroquinolones; Ketolides; Macrolides; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ofloxacin; Oxazolidinones; Quinolines; Spain | 2003 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydophila pneumoniae; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Indoles; Levofloxacin; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Topoisomerase II Inhibitors | 2003 |
In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Genes, Bacterial; Gonorrhea; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Nalidixic Acid; Naphthyridines; Neisseria gonorrhoeae; Ofloxacin; Quinolines | 2003 |
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Streptococcus pneumoniae | 2003 |
A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function.
Topics: Administration, Oral; Anti-Bacterial Agents; Aza Compounds; Costs and Cost Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Formularies, Hospital as Topic; Gatifloxacin; Humans; Infusions, Intravenous; Kidney; Kidney Function Tests; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Corneal Ulcer; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2003 |
Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells.
Topics: Adjuvants, Immunologic; Anti-Infective Agents; Aza Compounds; Blotting, Western; Ceftriaxone; Cell Survival; Cephalosporins; Cytokines; Enzyme-Linked Immunosorbent Assay; Escherichia coli; Flow Cytometry; Fluoroquinolones; Humans; I-kappa B Proteins; In Vitro Techniques; Interleukin-6; Lipopolysaccharide Receptors; Monocytes; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae; Tumor Necrosis Factor-alpha | 2003 |
In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV.
Topics: Analysis of Variance; Aza Compounds; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Pharmacogenetics; Pneumococcal Infections; Probability; Quinolines; Reference Values; Regression Analysis; Sensitivity and Specificity; Streptococcus pneumoniae | 2003 |
Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
Topics: Aza Compounds; Base Sequence; Ciprofloxacin; DNA Gyrase; DNA Primers; DNA Topoisomerase IV; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Ofloxacin; Polymerase Chain Reaction; Quinolines | 2004 |
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Neutropenia; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Treatment Failure | 2004 |
Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Body Fluids; Cells, Cultured; Colony Count, Microbial; Culture Media; DNA Topoisomerase IV; DNA, Bacterial; Epithelium; Fluoroquinolones; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Phenotype; Quinolines; Streptococcus pneumoniae | 2004 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection | 2004 |
Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Colony Count, Microbial; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Lung; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Streptococcus pneumoniae | 2004 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cornea; Drug Resistance, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Staphylococcal Infections | 2004 |
Recurrent tendinitis after treatment with two different fluoroquinolones.
Topics: Achilles Tendon; Aged; Anti-Infective Agents; Asthma; Aza Compounds; Female; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Recurrence; Tendinopathy; Ultrasonography | 2004 |
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Clindamycin; Disease Models, Animal; Fluoroquinolones; Injections, Subcutaneous; Levofloxacin; Male; Metronidazole; Mice; Moxifloxacin; Ofloxacin; Quinolines | 2004 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Movement; Chemokines; Chlamydia; Endothelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytes; Pneumonia, Bacterial; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha; Umbilical Veins | 2004 |
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Serratia Infections; Serratia marcescens | 2004 |
Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Enterobacteriaceae; Enterococcus faecalis; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2004 |
Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Body Temperature; Colony Count, Microbial; Disease Models, Animal; Female; Fluoroquinolones; Levofloxacin; Lung; Mice; Moxifloxacin; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Skin Temperature | 2004 |
Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; DNA, Bacterial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Streptococcus pneumoniae | 2004 |
Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching.
Topics: Anti-Infective Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Hydrogen-Ion Concentration; Levofloxacin; Moxifloxacin; Ofloxacin; Quality Control; Quinolines; Reference Standards; Reproducibility of Results | 2004 |
Penetration of newer quinolones in the empyema fluid.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Empyema, Pleural; Escherichia coli Infections; Fluoroquinolones; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pleural Effusion; Quinolines; Rabbits | 2004 |
Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2004 |
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Structure-Activity Relationship; Time Factors | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Chromatography, High Pressure Liquid; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Half-Life; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line, Tumor; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Time Factors | 2005 |
Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
Vibrational spectroscopic characterization of fluoroquinolones.
Topics: Aza Compounds; Cinoxacin; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Enoxacin; Enzyme Inhibitors; Fluoroquinolones; Hydrogen Bonding; Hydrogen-Ion Concentration; Models, Chemical; Models, Molecular; Models, Theoretical; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Oxolinic Acid; Quinolines; Quinolones; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Temperature; Ultraviolet Rays; Vibration; Water | 2005 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Aza Compounds; Cell Line; Cell Movement; Chemokine CCL2; Chlamydia Infections; Chlamydophila pneumoniae; Endothelium, Vascular; Fluoroquinolones; Gatifloxacin; Humans; Interleukin-8; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytosis; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha | 2005 |
Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Ciprofloxacin; Fluoroquinolones; Heat-Shock Response; Humans; Kinetics; Levofloxacin; Macrophages; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2005 |
In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
Topics: Amoxicillin; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Sampling Studies; Sensitivity and Specificity; Streptococcus pneumoniae | 2005 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Erythromycin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2005 |
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Moxifloxacin; Mutagenicity Tests; Naphthyridines; Ofloxacin; Quinolines; Selection, Genetic; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |
[In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clindamycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Staphylococcus aureus; Staphylococcus epidermidis | 2005 |
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2005 |
Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Point Mutation; Quinolines; Sequence Analysis, DNA | 2005 |
Glucose homeostasis abnormalities associated with use of gatifloxacin.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
Levofloxacin and moxifloxacin increase human gut colonization by Candida species.
Topics: Anti-Infective Agents; Aza Compounds; Candida; Drug Resistance, Microbial; Fluoroquinolones; Humans; Intestines; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigen-Presenting Cells; Aza Compounds; Cell Proliferation; Cells, Cultured; Ciprofloxacin; Clone Cells; Cross Reactions; Drug Hypersensitivity; Enoxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Delayed; Middle Aged; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Patch Tests; Pipemidic Acid; Quinolines; Quinolones; T-Lymphocytes | 2006 |
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits | 2006 |
Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Aza Compounds; Database Management Systems; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Sinusitis; Treatment Outcome; United States | 2006 |
Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Cell Line; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Moxifloxacin; Ofloxacin; Quinolines | 2006 |
Glucose homeostasis abnormalities and gatifloxacin.
Topics: Aza Compounds; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Moxifloxacin; Ofloxacin; Quinolines | 2006 |
Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations.
Topics: Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; Klebsiella pneumoniae; Levofloxacin; Lung; Models, Biological; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |
Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Mice; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Survival Analysis | 2006 |
Validation of a levofloxacin HPLC assay in plasma and dialysate for pharmacokinetic studies.
Topics: Anti-Bacterial Agents; Aza Compounds; Chromatography, High Pressure Liquid; Dialysis Solutions; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Renal Dialysis; Reproducibility of Results | 2006 |
In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals.
Topics: Anti-Bacterial Agents; Aza Compounds; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Fusidic Acid; Humans; In Vitro Techniques; Levofloxacin; Malaysia; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Rifampin; Staphylococcus aureus; Virginiamycin | 2005 |
Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2006 |
Determination of the newer quinolones levofloxacin and moxifloxacin in plasma by high-performance liquid chromatography with fluorescence detection.
Topics: Anti-Bacterial Agents; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 2006 |
Determination of ofloxacin and moxifloxacin and their penetration in human aqueous and vitreous humor by using high-performance liquid chromatography fluorescence detection.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Chromatography, High Pressure Liquid; Fluorescence; Fluoroquinolones; Humans; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Vitreous Body | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Enterococcus; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; In Vitro Techniques; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pyrrolidines; Quinolines; Quinolones; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes | 2006 |
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Vitreous Body | 2007 |
In vitro activity of fluoroquinolones against common respiratory pathogens.
Topics: Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Serum Bactericidal Test; Streptococcus pneumoniae | 2006 |
Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Topics: Adult; Area Under Curve; Aza Compounds; Bronchi; Computer Simulation; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Levofloxacin; Lung; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Moxifloxacin prophylaxis in neutropenic patients.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteremia; Clostridioides difficile; Enterocolitis, Pseudomembranous; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Moxifloxacin; Neutropenia; Ofloxacin; Quinolines | 2006 |
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Horses; Humans; Injections, Intravenous; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2006 |
Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
Topics: Aged; Aged, 80 and over; Aza Compounds; Case-Control Studies; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines | 2006 |
Increased polymorphonuclear leukocyte respiratory burst function in type 2 diabetes.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Fluoroquinolones; Humans; Male; Mexican Americans; Moxifloxacin; Neutrophils; Ofloxacin; Protein Kinase C; Quinolines; Respiratory Burst; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 2007 |
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae | 2007 |
Evaluation of the penetration of fluoroquinolones in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2006 |
Photophysical and phototoxic properties of the antibacterial fluoroquinolones levofloxacin and moxifloxacin.
Topics: 3T3 Cells; Animals; Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Radiation; Erythrocytes; Fluoroquinolones; Humans; Levofloxacin; Lipid Peroxidation; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Photolysis; Photosensitizing Agents; Quinolines; Ultraviolet Rays | 2004 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae | 2007 |
In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Brazil; Ciprofloxacin; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Incidence; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2007 |
Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Cross Infection; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Risk Factors | 2007 |
The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Hungary; Microbial Sensitivity Tests; Moxifloxacin; Mutation, Missense; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2006 |
Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
Topics: Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2007 |
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae].
Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin | 2007 |
Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Culture Media; Epithelium; Fluoroquinolones; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2007 |
Delayed intraocular foreign body removal without endophthalmitis during Operations Iraqi Freedom and Enduring Freedom.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Combined Modality Therapy; Endophthalmitis; Eye Enucleation; Eye Foreign Bodies; Eye Injuries, Penetrating; Female; Fluoroquinolones; Follow-Up Studies; Humans; Iraq; Levofloxacin; Male; Middle Aged; Military Medicine; Military Personnel; Moxifloxacin; Ofloxacin; Postoperative Complications; Prognosis; Quinolines; Retrospective Studies; Risk Factors; Time Factors; Visual Acuity; Vitrectomy; Vitreoretinopathy, Proliferative; Warfare | 2007 |
Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Aza Compounds; Cell Line; Extracellular Space; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Levofloxacin; Lysosomes; Monocytes; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus | 2007 |
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Electrophysiologic Techniques, Cardiac; Fluoroquinolones; Heart Conduction System; In Vitro Techniques; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Rabbits; Torsades de Pointes | 2007 |
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Ciprofloxacin; Drug Combinations; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus | 2007 |
Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Topics: Anti-Infective Agents; Antimutagenic Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Eye; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Osmolar Concentration; Quinolines | 2007 |
Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteriological Techniques; Cell Count; Cell Survival; Cells, Cultured; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; Epithelium, Corneal; Fluoroquinolones; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Quinolines; Serratia marcescens; Staphylococcus aureus | 2007 |
Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Bacterial Agents; Anuria; Aza Compounds; Critical Care; Critical Illness; Female; Fluoroquinolones; Humans; Intensive Care Units; Levofloxacin; Male; Metabolic Clearance Rate; Middle Aged; Moxifloxacin; Multiple Organ Failure; Ofloxacin; Quinolines; Renal Dialysis; Sepsis | 2006 |
In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Topics: Animals; Aza Compounds; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Japan; Levofloxacin; Liver; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolines; Spleen | 2007 |
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Quinolines; Streptococcus pneumoniae | 2008 |
Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens.
Topics: Abdominal Cavity; Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria, Aerobic; Bacteria, Anaerobic; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Serum Bactericidal Test | 2008 |
Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Colony Count, Microbial; DNA Topoisomerases; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Mutation, Missense; Ofloxacin; Polymerase Chain Reaction; Quinolines; Sequence Analysis, DNA; Streptococcus pneumoniae | 2008 |
Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells.
Topics: Anti-Bacterial Agents; Aza Compounds; Biological Assay; Ciprofloxacin; Cornea; Corneal Stroma; Endothelial Cells; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cytokines; Disease Models, Animal; Fluoroquinolones; Levofloxacin; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Distress Syndrome | 2008 |
Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Topics: Animals; Anti-Inflammatory Agents; Aza Compounds; Cells, Cultured; Conjunctivitis; Endotoxins; Fluoroquinolones; Gatifloxacin; Immunologic Factors; Keratitis; Levofloxacin; Lipopolysaccharides; Macrophages, Peritoneal; Male; Methicillin Resistance; Mice; Mice, Inbred C3H; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Tumor Necrosis Factor-alpha | 2008 |
Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty.
Topics: Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Aza Compounds; Bone and Bones; Chromatography, High Pressure Liquid; Female; Fluoroquinolones; Humans; Injections, Intravenous; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Osteomyelitis; Quinolines | 2007 |
In vitro susceptibilities of bacterial isolates from conjunctival flora to gatifloxacin, levofloxacin, tosufloxacin, and moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacteria; Child; Conjunctiva; Drug Resistance, Microbial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2008 |
Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
Topics: Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Predictive Value of Tests; Quinolines; Stenotrophomonas maltophilia | 2008 |
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Female; Fluoroquinolones; Health Care Costs; Hospitalization; Humans; Infusions, Intravenous; Insurance Claim Review; Length of Stay; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Research Design; Retrospective Studies; Treatment Outcome; United States | 2008 |
Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
Topics: Aza Compounds; Conjunctiva; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, MDR; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Staphylococcus epidermidis | 2008 |
Moxifloxacin for bacterial keratitis.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Cefazolin; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Ofloxacin; Quinolines; Randomized Controlled Trials as Topic; Tobramycin; Treatment Outcome | 2008 |
Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria monocytogenes.
Topics: Anti-Bacterial Agents; Aza Compounds; Cell Line, Tumor; Colony Count, Microbial; Cytoplasm; Fluoroquinolones; Humans; Levofloxacin; Listeria monocytogenes; Microbial Viability; Monocytes; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2008 |
Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using levofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study.
Topics: Administration, Oral; Analytic Sample Preparation Methods; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Sensitivity and Specificity | 2008 |
Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Aza Compounds; Cefazolin; Cell Count; Cornea; Endothelium, Corneal; Fluoroquinolones; Injections; Levofloxacin; Microscopy, Electron, Scanning; Moxifloxacin; Ofloxacin; Quinolines; Rabbits | 2008 |
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; Colony Count, Microbial; Cytotoxins; DNA Gyrase; Feces; Fluoroquinolones; Gastrointestinal Tract; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Ribotyping | 2009 |
Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Cross-Sectional Studies; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines; Retrospective Studies | 2008 |
Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Cell Survival; Ciprofloxacin; Conjunctiva; Drug Evaluation, Preclinical; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tetrazolium Salts; Thiazoles | 2008 |
Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.
Topics: Animals; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Fluoroquinolones; Gatifloxacin; Humans; Isoenzymes; Levofloxacin; Microsomes, Liver; Molecular Structure; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results | 2008 |
Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV.
Topics: Acetamides; Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Oxazolidinones; Quality Control; Quinolines; Reference Standards; Reproducibility of Results; Rifampin; Solutions; Solvents; Spectrophotometry, Ultraviolet | 2009 |
The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacteria, Aerobic; Ciprofloxacin; Conjunctiva; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aspergillus fumigatus; Aza Compounds; Candida albicans; Ciprofloxacin; Drug Antagonism; Drug Synergism; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Foreign Bodies; Levofloxacin; Male; Microbial Sensitivity Tests; Microbial Viability; Models, Animal; Moxifloxacin; Ofloxacin; Quinolines; Rats; Rats, Wistar; Staphylococcal Infections; Time Factors | 2009 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Humans; India; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Retrospective Studies; Staphylococcus; Streptococcus | 2010 |
Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Brucella melitensis; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Norfloxacin; Ofloxacin; Quinolines; Sequence Analysis, DNA | 2009 |
Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Conjunctiva; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Preoperative Care; Quinolines | 2009 |
Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma.
Topics: Aza Compounds; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Humans; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
Topics: Aza Compounds; Clostridioides difficile; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2009 |
Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Bacterial Agents; Antitubercular Agents; Aspartate Aminotransferases; Aza Compounds; Ethambutol; Female; Fluoroquinolones; Hepatic Insufficiency; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Streptomycin; Treatment Outcome; Tuberculosis; Young Adult | 2009 |
Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Neisseria gonorrhoeae; Ofloxacin; Quinolines; Selection, Genetic | 2009 |
Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Survival; Cells, Cultured; Ciprofloxacin; Electric Impedance; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2010 |
Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2009 |
Validation of a MLC method with fluorescence detection for the determination of quinolones in urine samples by direct injection.
Topics: Anti-Bacterial Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluorescence; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Reproducibility of Results | 2009 |
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Ambulatory Care; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Costs and Cost Analysis; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Outpatients; Pneumonia; Quinolines; Young Adult | 2010 |
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Polymerase Chain Reaction; Quinolines; Streptococcus pneumoniae | 2010 |
[Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Mice; Moxifloxacin; Ofloxacin; Plague; Quinolines; Species Specificity; Time Factors; Yersinia pestis | 2009 |
Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteriological Techniques; Ciprofloxacin; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae; Time Factors | 2010 |
A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease.
Topics: Adolescent; Adult; Anti-Infective Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metronidazole; Middle Aged; Moxifloxacin; Ofloxacin; Pelvic Inflammatory Disease; Quinolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2010 |
Colonisation of fluoroquinolone-resistant Haemophilus influenzae among nursing home residents in southern Taiwan.
Topics: Aged; Aza Compounds; beta-Lactamases; Colony Count, Microbial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Male; Moxifloxacin; Nursing Homes; Ofloxacin; Prospective Studies; Quinolines; Risk Factors; Serotyping; Taiwan | 2010 |
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
Topics: Aminopyridines; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium avium Complex; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium kansasii; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Quinolines; Rifampin; Species Specificity | 2010 |
Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Cefepime; Cefoperazone; Cephalosporins; Female; Fetal Blood; Fluoroquinolones; Humans; Infant, Newborn; Injections, Intravenous; Levofloxacin; Maternal-Fetal Exchange; Moxifloxacin; Ofloxacin; Pregnancy; Pregnancy Complications, Infectious; Quinolines | 2010 |
Maternal blood and amniotic fluid levels of moxifloxacin, levofloxacin and cefixime.
Topics: Adult; Amniocentesis; Amniotic Fluid; Anti-Bacterial Agents; Aza Compounds; Cefixime; Female; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Pregnancy; Quinolines; Statistics, Nonparametric | 2010 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline | 2010 |
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2010 |
Effects of levofloxacin, moxifloxacin and prulifloxacin on murine gut colonization by Candida albicans.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Candida albicans; Dioxolanes; Feces; Fluoroquinolones; Gastrointestinal Tract; Levofloxacin; Male; Mice; Mice, Inbred ICR; Models, Animal; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Sodium Chloride | 2011 |
Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Aza Compounds; Bacteremia; Drug Resistance, Bacterial; Drug Utilization; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Spain; Young Adult | 2011 |
[Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
Topics: Anti-Bacterial Agents; Aza Compounds; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mutation; Ofloxacin; Otorhinolaryngologic Diseases; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2010 |
Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Microbial Viability; Models, Biological; Models, Theoretical; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Staphylococcus aureus; Time Factors | 2011 |
Primary resistance of Helicobacter pylori to levofloxacin and moxifloxacine in Iran.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Iran; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Young Adult | 2012 |
Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2011 |
Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; Cricetinae; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Mesocricetus; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Prohibitins; Quinolines | 2011 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline | 2011 |
JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2011 |
Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Doxycycline; Erythromycin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Roxithromycin; Tetracycline; Time Factors; Ureaplasma Infections; Ureaplasma urealyticum | 2011 |
Comparison of the chromatographic behavior of levofloxacin, ciprofloxacin and moxifloxacin on various HPLC phases.
Topics: Anti-Bacterial Agents; Aza Compounds; Calixarenes; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Indicators and Reagents; Ions; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Solutions | 2011 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2011 |
Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.
Topics: Adult; Antitubercular Agents; Aza Compounds; Bacterial Proteins; DNA, Bacterial; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Molecular Typing; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence; Quinolines; Sequence Analysis, DNA; Texas | 2011 |
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Topics: Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Chi-Square Distribution; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Odds Ratio; Ofloxacin; Quinolines; Recurrence; Remission Induction; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2011 |
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain; Tuberculosis | 2011 |
[The effectiveness of intraocular delivery of 5-fluoroquinolones for prophylaxis of intraocular infection].
Topics: Anti-Bacterial Agents; Aza Compounds; Eye Infections, Bacterial; Eye Injuries; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intraocular; Levofloxacin; Male; Military Medicine; Moxifloxacin; Ofloxacin; Quinolines; Warfare | 2011 |
In vitro comparison of the cytotoxic effects of clinically available ophthalmic solutions of fluoroquinolones on human keratocytes.
Topics: Anti-Bacterial Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Corneal Keratocytes; Culture Media; Fluoroquinolones; Gatifloxacin; Humans; L-Lactate Dehydrogenase; Microscopy, Phase-Contrast; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2011 |
Comparison of moxifloxacin and levofloxacin in an epithelial disorder model using cultured rabbit corneal epithelial cell sheets.
Topics: Amnion; Animals; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Corneal Diseases; Epithelium, Corneal; Female; Fluoroquinolones; Levofloxacin; Models, Biological; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines; Rabbits; Swine; Wound Healing | 2012 |
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Geography; Haemophilus influenzae; Humans; Inhibitory Concentration 50; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Streptococcus pneumoniae | 2012 |
Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Space; Fluoroquinolones; Intracellular Space; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Peritonitis; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2012 |
gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation, Missense; Mycobacterium tuberculosis; Ofloxacin; Polymorphism, Single Nucleotide; Quinolines | 2012 |
Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection.
Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Case-Control Studies; Conjunctiva; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Intravitreal Injections; Macular Degeneration; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Polymyxin B; Quinolines; Trimethoprim | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Gemifloxacin; Glycosides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifamycins; Rifaximin; Taiwan; Vancomycin | 2012 |
Induction of mycobacterial resistance to quinolone class antimicrobials.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2012 |
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Tract Infections; Thailand; Urinary Tract Infections | 2012 |
The effect of levofloxacin and moxifloxacin on cardiovascular functions of rats with streptozotocin-induced diabetes.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Biological Factors; Blood Glucose; Bradycardia; Cardiovascular System; Diabetes Mellitus, Experimental; Electrocardiography; Endothelium, Vascular; Fluoroquinolones; Heart; Heart Rate; Hypoglycemia; Intermediate-Conductance Calcium-Activated Potassium Channels; Levofloxacin; Male; Mesenteric Arteries; Moxifloxacin; Ofloxacin; Quinolines; Rats; Rats, Wistar; Small-Conductance Calcium-Activated Potassium Channels; Streptozocin | 2013 |
In vitro assessment of the cytotoxicity of six topical antibiotics to four cultured ocular surface cell lines.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cefmenoxime; Cell Line; Cell Survival; Conjunctiva; Cornea; Dibekacin; Dose-Response Relationship, Drug; Epithelial Cells; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines; Rabbits | 2012 |
Treatment of tuberculosis with levofloxacin or moxifloxacin: report of 6 pediatric cases.
Topics: Adolescent; Antitubercular Agents; Aza Compounds; Child; Child, Preschool; Female; Fluoroquinolones; France; Hospitals, University; Humans; Infant; Levofloxacin; Male; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2012 |
Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcal Skin Infections; Staphylococcus aureus | 2012 |
Photodegradation of fluoroquinolones in surface water and antimicrobial activity of the photoproducts.
Topics: Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Photolysis; Quinolines; Tandem Mass Spectrometry | 2012 |
Evidence of in vivo prophage induction during Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; DNA, Viral; Feces; Fluoroquinolones; Genetic Variation; Genome, Viral; Humans; Levofloxacin; Lysogeny; Microbial Sensitivity Tests; Mitomycin; Molecular Sequence Data; Moxifloxacin; Myoviridae; Ofloxacin; Prophages; Quinolines; Sequence Analysis, DNA; Virus Activation | 2012 |
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
Topics: Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Russia; Tuberculosis, Pulmonary | 2013 |
Moxifloxacin as postoperative prophylaxis for Enterococcus faecalis-induced endophthalmitis after cataract surgery in aphakic rabbits.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aphakia, Postcataract; Aza Compounds; Disease Models, Animal; Electroretinography; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Fluoroquinolones; Gram-Positive Bacterial Infections; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Phacoemulsification; Quinolines; Rabbits; Time Factors | 2013 |
Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Load; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Models, Theoretical; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Selection, Genetic; Streptococcus pneumoniae | 2013 |
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Levofloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis | 2013 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis | 2013 |
Rationalizing use of fluoroquinolones and pyrazinamide in the battle against multidrug-resistant tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Female; Fluoroquinolones; Moxifloxacin; Ofloxacin; Pyrazinamide; Quinolines; Tuberculosis | 2013 |
[Achilles heel of COPD].
Topics: Achilles Tendon; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aza Compounds; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyspnea; Fluoroquinolones; Humans; Male; Mobility Limitation; Moxifloxacin; Ofloxacin; Prednisone; Pulmonary Disease, Chronic Obstructive; Quinolines; Respiratory Insufficiency; Rupture, Spontaneous; Ultrasonography | 2013 |
Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
Topics: Amikacin; Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Administration Schedule; Drug Resistance, Bacterial; Ethionamide; Female; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Recurrence; Rodent Diseases; Survival Analysis; Tuberculosis | 2013 |
Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Aza Compounds; Desiccation; Drug Carriers; Drug Compounding; Drug Design; Fluoroquinolones; Gases; Moxifloxacin; Nanoparticles; Ofloxacin; Particle Size; Powders; Quinolines; Solutions | 2013 |
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence | 2014 |
Antibacterial activity of moxifloxacin on bacteria associated with periodontitis within a biofilm.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacterial Physiological Phenomena; Biofilms; Doxycycline; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Ofloxacin; Periodontitis; Quinolines | 2014 |
Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Topics: Adolescent; Adult; Amikacin; Antitubercular Agents; Cycloserine; Ethionamide; Female; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Sputum; Tanzania; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Registries; Republic of Korea; Retrospective Studies; Tertiary Care Centers; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2014 |
Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; India; Kanamycin; Microbial Sensitivity Tests; Microscopy; Moldova; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Peru; Predictive Value of Tests; Reproducibility of Results; South Africa; Sputum; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
Degradation of fluoroquinolone antibiotics and identification of metabolites/transformation products by liquid chromatography-tandem mass spectrometry.
Topics: Anti-Bacterial Agents; Aza Compounds; Biotransformation; Chromatography, Liquid; Ciprofloxacin; Fluoroquinolones; Moxifloxacin; Norfloxacin; Ofloxacin; Photolysis; Quinolines; Tandem Mass Spectrometry | 2014 |
The effect of some fluoroquinolone family members on biospeciation of copper(II), nickel(II) and zinc(II) ions in human plasma.
Topics: Ciprofloxacin; Coordination Complexes; Copper; Fluoroquinolones; Humans; Ions; Levofloxacin; Moxifloxacin; Nickel; Ofloxacin; Zinc | 2014 |
Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
Topics: Antitubercular Agents; DNA Gyrase; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin | 2015 |
Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over time.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Ethionamide; Female; Fluoroquinolones; Humans; India; Infant; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Precision Medicine; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2015 |
Proteome analysis of ofloxacin and moxifloxacin induced mycobacterium tuberculosis isolates by proteomic approach.
Topics: Bacterial Proteins; Computational Biology; Fluoroquinolones; Molecular Docking Simulation; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Proteome; Proteomics; Topoisomerase II Inhibitors | 2015 |
Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.
Topics: Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult | 2015 |
Simultaneous determination of fluoroquinolones in environmental water by liquid chromatography-tandem mass spectrometry with direct injection: A green approach.
Topics: Anti-Bacterial Agents; Brazil; Chromatography, Liquid; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Fresh Water; Gemifloxacin; Green Chemistry Technology; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical | 2015 |
Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Topics: Anti-Bacterial Agents; Asian People; Codon; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Europe; Fluoroquinolones; Gene Expression; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Prevalence; Taiwan; Tuberculosis, Multidrug-Resistant; United States; White People | 2016 |
Simultaneous determination of moxifloxacin and ofloxacin in physiological fluids using high performance liquid chromatography with ultraviolet detection.
Topics: Animals; Anti-Bacterial Agents; Body Fluids; Cattle; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Limit of Detection; Moxifloxacin; Ofloxacin; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2016 |
Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis.
Topics: Aged; Antitubercular Agents; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Taiwan; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2016 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin.
Topics: Antitubercular Agents; China; DNA Gyrase; Drug Dosage Calculations; Drug Resistance, Bacterial; Fluoroquinolones; Gene Expression; Genotype; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Tuberculosis, Pulmonary | 2016 |
In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genotyping Techniques; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Selection, Genetic; Tuberculosis | 2016 |
Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.
Topics: DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Genetic Fitness; Genomics; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Ofloxacin; Sequence Analysis, DNA; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2017 |
Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyes.
Topics: Aqueous Humor; Bayes Theorem; Cadaver; Ciprofloxacin; Cornea; Eye Enucleation; Fluoroquinolones; Humans; Moxifloxacin; Ofloxacin | 2017 |
Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment.
Topics: Aminosalicylic Acid; Antitubercular Agents; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Streptomycin; Taiwan | 2018 |
Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; India; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prevalence; Prospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2018 |
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data.
Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin; Sequence Analysis, DNA; Streptomycin; Tuberculosis, Multidrug-Resistant | 2018 |
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant | 2018 |
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Case-Control Studies; Ciprofloxacin; Female; Fluoroquinolones; Humans; Incidence; Levofloxacin; Male; Middle Aged; Moxifloxacin; Norfloxacin; Ofloxacin; Peripheral Nervous System Diseases; Risk Factors; Sex Factors; United Kingdom | 2019 |
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Moxifloxacin; Ofloxacin; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response.
Topics: Antitubercular Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Polymorphism, Single Nucleotide | 2019 |
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Topics: Antitubercular Agents; China; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pharmaceutical Preparations; Prospective Studies; Tuberculosis, Multidrug-Resistant | 2021 |
Acceptability of levofloxacin, moxifloxacin and linezolid among children and adolescents treated for TB.
Topics: Adolescent; Anti-Bacterial Agents; Aza Compounds; Child; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Tuberculosis | 2020 |
A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Adverse Drug Reaction Reporting Systems; Arthralgia; Ciprofloxacin; Connective Tissue Diseases; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Musculoskeletal Diseases; Myalgia; Norfloxacin; Ofloxacin; Pain; Risk Factors; Tendinopathy; Tendons; Young Adult | 2021 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Retrospective Studies; Tertiary Care Centers; Vancomycin | 2022 |
Use of Whole-Genome Sequencing to Predict
Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Drug Resistance; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Streptomycin; Tuberculosis, Multidrug-Resistant | 2022 |
A molecularly imprinted polymer nanoparticle-based surface plasmon resonance sensor platform for antibiotic detection in river water and milk.
Topics: Allergens; Animals; Anti-Bacterial Agents; Ciprofloxacin; Milk; Molecular Imprinting; Molecularly Imprinted Polymers; Moxifloxacin; Nanoparticles; Ofloxacin; Rivers; Surface Plasmon Resonance; Water | 2022 |
Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI-TOF-MS.
Topics: Amikacin; Antitubercular Agents; China; Drug Resistance; Ethambutol; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nucleotides; Ofloxacin; Rifampin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Streptomycin; Tuberculosis, Lymph Node | 2022 |
Promising Antimicrobial Activity and Synergy of Bacteriocins Against
Topics: Antitubercular Agents; Bacteriocins; Drug Synergism; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Rifampin | 2023 |
Antibiotics and antimycotics in waste water treatment plants: Concentrations, removal efficiency, spatial and temporal variations, prediction, and ecological risk assessment.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clotrimazole; Environmental Monitoring; Moxifloxacin; Norfloxacin; Ofloxacin; Pefloxacin; Risk Assessment; Sewage; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Water Purification | 2022 |
Introduction of maltodextrin nanosponges as green extraction phases: Magnetic solid phase extraction of fluoroquinolones.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Magnetic Phenomena; Moxifloxacin; Ofloxacin; Polysaccharides; Solid Phase Extraction; Wastewater; Water | 2022 |
Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020.
Topics: Anti-Bacterial Agents; Cefuroxime; Ciprofloxacin; Colistin; Eye Infections; Fluoroquinolones; Gatifloxacin; Humans; Longitudinal Studies; Moxifloxacin; Ofloxacin; Retrospective Studies | 2022 |
Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Drug Screening Assays, Antitumor; Fluoroquinolones; Humans; Molecular Structure; Moxifloxacin; Ofloxacin; Structure-Activity Relationship | 2023 |
Occurrence, distribution, and risk assessment of quinolone antibiotics in municipal sewage sludges throughout China.
Topics: Anti-Bacterial Agents; China; Environmental Monitoring; Humans; Moxifloxacin; Ofloxacin; Quinolones; Risk Assessment; Sewage; Water Pollutants, Chemical | 2023 |
In-Class Cross-Reactivity among Hospitalized Patients with Hypersensitivity Reactions to Fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Hypersensitivity; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2023 |
Validated spectrofluorimetric assay of two co-administered drug mixtures containing hydroxychloroquine with either moxifloxacin or ofloxacin as a drug regimen for hospital-acquired pneumonia in patients with COVID-19.
Topics: Anti-Bacterial Agents; COVID-19; COVID-19 Drug Treatment; Hospitals; Humans; Hydroxychloroquine; Moxifloxacin; Ofloxacin; Pandemics; Spectrometry, Fluorescence | 2023 |